Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 872 across all filing types
Latest filing 2017-09-28 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Communications during bidding periods / Other releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing clinical trial results for a drug candidate (ABX464). It details the methodology, results, and future plans for the study, and includes information about an upcoming webcast presentation. This type of document, which provides updates on company research and development activities, is classified as a Regulatory Filing (RNS) as it does not fit into specific financial report categories like 10-K or IR, and it is not a standalone investor presentation or call transcript. FY 2017
2017-09-28 English
ABIVAX gibt Halbjahresergebnisse 2017 und Unternehmens-Update bekannt
Earnings Release Classification · 1% confidence The document is titled "ABIVAX gibt Halbjahresergebnisse 2017 und Unternehmens-Update bekannt" (ABIVAX announces 2017 half-year results and business update). It explicitly details financial results for the first half of 2017 ("HIGHLIGHTS H1 2017", "FINANZKENNZAHLEN H1 2017"), including a loss for the period and balance sheet data as of June 30, 2017. This content structure—comprehensive financial figures and operational updates for a period shorter than a year—is characteristic of an Interim/Quarterly Report. Although it contains an update, the core is the financial reporting for the half-year period, making 'IR' (Interim / Quarterly Report) the most appropriate classification over 'ER' (Earnings Release, which is usually just highlights) or 'MDA' (Management Reports, which is more narrative). It is not a full Annual Report (10-K). H1 2017
2017-09-20 German
ABIVAX erhalt Zulassung der franzosischen Behorden fur den Start einer klinischen Studie mit ABX464 zur Behandlung von Colitis ulcerosa
Legal Proceedings Report Classification · 1% confidence The document is a press release dated September 20, 2017, announcing that ABIVAX received approval from the French authorities (ANSM) to start a Phase-2a clinical study for its drug candidate ABX464 in treating Ulcerative Colitis. It details the study design, expected timeline, and includes quotes from management and investigators. This type of announcement, focusing on clinical trial progress and regulatory milestones, is characteristic of a general corporate news release or regulatory filing that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a specific announcement about clinical development and regulatory clearance, and not a general regulatory filing fallback (RNS), it most closely aligns with a general corporate announcement. Given the options, and since it is not a financial report, management change, or dividend notice, it falls under the general regulatory/news announcement category. However, since it is a specific announcement about a clinical trial, it is best classified as a Regulatory Filing (RNS) as it is a formal communication to the market about a significant operational/regulatory event, or potentially a Legal Proceedings Report (LTR) if the focus was on litigation, but here it is about trial approval. Given the context of biotech news, RNS is the most appropriate general regulatory news category when a more specific category like 'LTR' (Legal) or 'CAP' (Financing) doesn't apply. It is not an Earnings Release (ER) or Interim Report (IR). It is a news release about a regulatory/clinical event.
2017-09-20 German
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release dated September 20, 2017, announcing that ABIVAX has received regulatory approval (from ANSM in France) to launch a Phase 2a clinical study for its drug candidate ABX464 in treating ulcerative colitis. It details the study design, objectives, and timeline. This type of announcement, focusing on clinical trial progress, regulatory milestones, and scientific updates, is typically classified as a general regulatory announcement or a specific update related to R&D/Clinical progress. Since there is no specific code for 'Clinical Trial Announcement' and it is not a formal financial report (10-K, IR, ER), nor a management change (MANG) or dividend notice (DIV), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements that don't fit elsewhere, especially those concerning regulatory interactions and trial initiation. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Audit Report (AR). Given the nature of the announcement (regulatory approval for a clinical trial), RNS is the most appropriate fit among the provided options.
2017-09-20 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated September 20th, 2017, announcing that ABIVAX received French regulatory approval (ANSM) to begin a Phase 2a clinical trial for ABX464 in Ulcerative Colitis. It details the study design, objectives, and quotes key personnel. This type of announcement, focusing on clinical trial progress, regulatory milestones, and general company updates outside of mandatory periodic financial filings (like 10-K or IR), typically falls under general regulatory announcements or investor relations material. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific transaction notice (DIV, SHA, POS), nor a management/board change (MANG), nor a proxy/governance document (DEF 14A, CGR), the most appropriate classification is the general regulatory announcement category, RNS, as it is a formal communication to the market about a significant operational/regulatory event.
2017-09-20 English
ABIVAX: ERSTER PATIENT DER DREI-MONATS-KOHORTE DER PHASE-2A-STUDIE MIT ORAL VERABREICHTEM ABX464 AN HIV-SUPPRIMIERTEN PATIENTEN BEHANDELT
Legal Proceedings Report Classification · 1% confidence The document is a press release dated September 18, 2017, announcing that the first patient in the second cohort of a Phase 2a clinical study (ABX464-005) for an HIV drug has been treated. It details the study's purpose (investigating the effect of ABX464 on HIV reservoirs), the dosing schedule, and expected results timelines. This type of announcement, focusing on clinical trial progress and key scientific updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive update about clinical progress rather than a summary of overall financial performance (ER) or a miscellaneous regulatory filing (RNS), and given the options, it most closely aligns with an Earnings Release (ER) as these often contain operational and clinical milestones, or RNS as a general announcement. However, because it is a specific news item about a clinical trial milestone, and not a formal quarterly earnings summary, RNS is a safer general classification for non-standard operational news, but ER often encompasses such operational updates when they are released outside of the formal quarterly report cycle. Given the structure (News Details, DGAP-News, Schlagwort: Studie), it functions as a timely operational update. Since there is no specific 'Clinical Trial Update' code, and it is not a full financial report (10-K, IR) or a presentation (IP), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company uses ERs broadly for operational news. Given the content is purely scientific/clinical progress, RNS (Regulatory Filings / General Announcement) is the most appropriate fallback for specific operational news that isn't a formal financial report or presentation.
2017-09-18 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.